Patents by Inventor Leslie BALCH

Leslie BALCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240182588
    Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
    Type: Application
    Filed: November 17, 2023
    Publication date: June 6, 2024
    Applicant: Vaccinex, Inc.
    Inventors: Pamela M. HOLLAND, Andrew LAKE, Austin DULAK, Ernest Smith, Maria Scrivens, Caroline Harvey, Renee Kirk, Leslie Balch, Sonia DAS, Christopher Converse Wells
  • Patent number: 11976383
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: May 7, 2024
    Assignee: VACCINEX, INC.
    Inventors: Ernest S. Smith, Maria G. M. Scrivens, Loretta Mueller, Shuying Shi, Leslie A. Balch
  • Publication number: 20240093177
    Abstract: This disclosure provides compositions and methods for high throughput screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target integral membrane protein.
    Type: Application
    Filed: June 12, 2023
    Publication date: March 21, 2024
    Inventors: Malgorzata Gil-Moore, Maria G.M Scrivens, Renee A. Kirk, Leslie A. Balch, Loretta L. Mueller, Ernest S. Smith
  • Patent number: 11859000
    Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: January 2, 2024
    Assignee: Vaccinex Inc.
    Inventors: Pamela M. Holland, Andrew Lake, Austin Dulak, Ernest Smith, Maria Scrivens, Caroline Harvey, Renee Kirk, Leslie Balch, Sonia G. Das, Christopher Converse Wells
  • Publication number: 20210348158
    Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.
    Type: Application
    Filed: May 5, 2021
    Publication date: November 11, 2021
    Inventors: Ernest S. Smith, Maria G.M. Scrivens, Loretta Mueller, Shuying Shi, Leslie A. Balch
  • Publication number: 20210238292
    Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
    Type: Application
    Filed: January 6, 2021
    Publication date: August 5, 2021
    Applicant: Vaccinex, Inc.
    Inventors: Pamela M. HOLLAND, Andrew LAKE, Austin DULAK, Ernest SMITH, Maria SCRIVENS, Carrie HARVEY, Renee KIRK, Leslie BALCH, Sonia G. DAS, Christopher Converse WELLS
  • Patent number: 10662422
    Abstract: The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 26, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Tracy Pandina, Leslie A. Balch, Mark Paris, Maurice Zauderer, Angelica Cornelison, Renee Kirk